MedLife announces its preliminary financial results for 2025, marking a stage of consolidation and transformation. The pro-forma consolidated turnover reached over RON 3.17 billion (approximately EUR 630 million), up by almost 17% compared to the previous year, while the pro-forma EBITDA reached RON 459 million in 2025.
“The economy is adjusting, and companies are feeling these changes. Consumption slowed down slightly, especially in the last quarter of 2025, but health remains a constant priority for Romanians. MedLife’s results remained solid, even in a challenging economic context. We believe that the recent measures are starting to take effect and the economy will return to a positive trend.
We look to the future with moderate optimism. The private sector continues to demonstrate its resilience: companies work, invest and actively contribute to the economy, even in difficult conditions.
MedLife remains one of the important pillars of the Romanian economy. The determination of the private sector, combined with a sustainable and predictable framework, is essential for Romania to turn current challenges into real opportunities for long-term growth” said Mihai Marcu, CEO & President of the Board of Directors of MedLife Group.
In 2025, the hospital division recorded a 27% increase compared to the previous year in terms of the number of hospitalizations, reaching over 200 thousand, laboratories processed over 10 million investigations, and clinics accumulated almost 5 million visits. Among the most requested services were consultations in gynecology, cardiology, advanced imaging (MRI, CT), complex laboratory tests and minimally invasive surgeries.
“We believe that the future of medicine lies in data, technology and prevention. Our genomic research approach is the expression of this vision. A project that opens paths, puts Romania on the map of genomic research and creates the premises for a paradigm shift in medicine, based on a personalized approach to the patient and a proactive therapeutic action”, said Mihai Marcu, CEO & President of the Board of Directors of MedLife Group.
In 2026, MedLife’s first major initiative is to bring genetic testing under the Longevity 100+ program to a large scale, providing patients with access to personalized prevention and diagnosis.
The Group will continue to explore strategic growth opportunities through acquisitions, especially in complementary areas such as aesthetics, sports and wellness, with the aim of strengthening integrated services.
In parallel, MedLife will focus on the development of niche centers, opening new horizons for specialized medicine and personalized services.